

Efficient synthesis of substituted bicyclic 2-pyridones by regioselective annulations of heterocyclic ketene aminals with methacrylic anhydride or crotonic anhydride

Jin Liu, Sheng-Jiao Yan*, Zheng-Mao Cao Shi-Sheng Cui and Jun Lin*

Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry Education, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, P. R. China. E-mail: yansj@ynu.edu.cn; linjun@ynu.edu.cn; Tel & Fax: +86 871 65031633.

Supporting Information


Table of Contents

General information	2
Procedure for synthesis of compound 3	2
Spectroscopic data of bicyclic pyridones derivatives 3	2
General procedure for the synthesis of bicyclic pyridones derivatives 4–5	3
Spectroscopic data of bicyclic pyridones derivatives 4–5	3
General procedure for the synthesis of compounds 6	13
Spectroscopic data of bicyclic pyridones derivatives 6	13
X-ray Structure and Data of 4j	15
¹ H NMR and ¹³ C NMR spectra for compound 3	19
¹ H NMR and ¹³ C NMR spectra for bicyclic pyridones 4	20
¹ H NMR and ¹³ C NMR spectra for bicyclic pyridones 5	34
¹ H NMR and ¹³ C NMR spectra for bicyclic pyridones 6	46
References.....	50

General information

All compounds were fully characterized by spectroscopic data. The NMR spectra were recorded on a Bruker Ascend III 600 or DRX500 (¹H: 600 or 500 MHz, ¹³C: 150 or 125 MHz). Chemical shifts (δ) are expressed in ppm and *J* values are given in Hz. Deuterated CDCl₃ and DMSO-*d*₆ were used as solvent. IR spectra were recorded on a FT-IR Thermo Nicolet Avatar 360 using a KBr pellet. The reactions were monitored by thin layer chromatography (TLC) using silica gel GF254. The melting points were determined on a XT-4A melting point apparatus and are uncorrected. HRMs were performed on an Agilent LC/Msd TOF instrument. Unless otherwise stated, all reagents used are commercially available. Solvents for reactions were purified by standard procedures. Compounds **1a–1n** were prepared according to the literature.¹ Materials **1o–1p** were synthesized according to the literature.²

Procedure for synthesis of compound 3




HKA **1h** (1.0 mmol), acetic anhydride (1.2 mmol) and dry CH₃CN (10 mL) were placed in a 25 mL round-bottom flask and trimethylamine (10 mmol%) was added and the mixture was stirred at reflux for 20 minutes. Upon completion, as monitored by TLC. Then the reaction mixture was cooled to room temperature and filtered to give the pure crude product, which was further washed with petroleum ether-EtOAc(1:1) to give pure product **3** with a yield of 94%.

Spectroscopic data of bicyclic pyridones derivatives 3

2-(1-Acetylimidazolidin-2-ylidene)-1-(*p*-tolyl)ethan-1-one (3)

White solid: mp 207–208°C; IR (KBr): 3449, 3168, 2091, 1691, 1604, 1496, 1391, 1310, 1256, 767 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆): δ = 10.21 (br, 1H, NH), 7.68 (d, *J* = 8.0 Hz, 2H, PhH), 7.25 (d, *J* = 7.9 Hz, 2H, PhH), 6.86 (s, 1H, C=CH), 4.03–3.63 (m, 4H, NCH₂CH₂), 2.34 (s, 3H, CH₃), 2.24 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ = 186.6, 170.2, 158.6, 140.7, 138.1, 129.2, 126.9, 79.0, 45.8, 42.0, 25.5, 21.3; HRMS (ESI) *m/z* calcd for C₁₄H₁₇N₂O₂ [M+H]⁺, 245.1285; found, 245.1284.


General procedure for the synthesis of bicyclic pyridones derivatives 4-5



HKA derivatives **1** (1.0 mmol) was added to a 25 mL round-bottom flask and dissolved in dry dioxane (10.0 mL). Methacrylic anhydride **2a** or crotonic anhydride **2b** (1.2 mmol) was added under stirring at room temperature, the mixture was stirred until TLC revealed that the conversion of the starting material was complete about 0.5-6 h. a small amount of H₂O (ca. 10 ml) was added and mixture was extracted with EtOAc (25 mL × 3). The combined organic extracts were dried over anhydrous Na₂SO₄ and evaporated *in vacuo*. The crude residue was dried and recrystallized from petroleum ether-EtOAc to afford the pure products **4-5** with a yield of 83-96%.


Spectroscopic data of bicyclic pyridones derivatives 4-5

7-Methyl-9-(4-methylbenzoyl)-1,2,3,4,7,8-hexahydro-6H-pyrido[1,2-*a*]pyrimidin-6-one (4a).




White solid: mp 157–158 °C; IR (KBr): 3423, 2967, 2815, 1695, 1605, 1575, 1241, 1155, 746 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 12.62 (br, 1H, NH), 7.23–7.22 (m, 2H, PhH), 7.19–7.17 (m, 2H, PhH), 3.84–3.56 (m, 2H, NCH₂), 3.44–3.36 (m, 2H, NCH₂), 3.48–3.44 (m, 2H, CH₂), 2.32 (s, 3H, CH₃), 2.31–2.26 (m, 1H, CH), 1.95–1.88 (m, 2H, CH₂), 1.03–1.02 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 187.3, 173.2, 156.5, 140.0, 138.3, 128.8, 127.2, 86.6, 39.6, 38.4, 30.0, 21.3, 20.7, 15.6; HRMS (ESI) *m/z* calcd for C₁₇H₂₁N₂O₂ [M+H]⁺, 285.1598; found, 285.1598.

9-(4-Methoxybenzoyl)-7-methyl-1,2,3,4,7,8-hexahydro-6H-pyrido[1,2-*a*]pyrimidin-6-one (4b)




White solid: mp 178–179 °C; IR (KBr): 3553, 3415, 2968, 1686, 1601, 1451, 1274, 1153, 837, 603 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 12.63 (br, 1H, NH), 7.31 (d, *J* = 8.6 Hz, 2H, PhH), 6.93 (d, *J* = 8.6 Hz, 2H, PhH), 3.85–3.57 (m, 2H, NCH₂), 3.78 (s, 3H, OCH₃), 3.42–3.33 (m, 2H, NCH₂), 2.51–2.50 (m, H, CH), 2.49–2.36 (m, 2H, CH₂), 1.94–1.89 (m, 2H, CH₂), 1.05–1.04 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 186.9, 173.1, 159.9, 156.4, 135.1, 129.0, 113.6, 86.6, 55.6, 39.9, 38.4, 36.3, 30.2, 20.7, 16.6; HRMS (ESI) *m/z* calcd for C₁₇H₂₁N₂O₃ [M+H]⁺, 301.1547; found, 301.1547.

9-(4-Chlorobenzoyl)-7-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (4c).



White solid: mp 135–136 °C; IR (KBr): 3439, 2966, 1698, 1612, 1542, 1402, 1241, 1177, 841 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 12.58 (br, 1H, NH), 7.45 (d, *J* = 8.3 Hz, 2H, PhH), 7.36 (d, *J* = 8.3 Hz, 2H, PhH), 3.83–3.44 (m, 2H, NCH₂), 3.38–3.36 (m, 2H, NCH₂), 2.50–2.39 (m, 2H, CH₂), 2.31–2.26 (m, H, CH), 1.95–1.90 (m, 2H, CH₂), 1.05–1.03 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 185.6, 173.1, 156.8, 141.4, 133.4, 129.2, 128.4, 86.7, 39.6, 38.4, 36.3, 29.8, 20.5, 15.6; HRMS (ESI) *m/z* calcd for C₁₆H₁₈ClN₂O₂ [M+H]⁺, 305.1051; found, 305.1052.


9-(4-Fluorobenzoyl)-7-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (4d).



Light yellow solid: mp 157–158 °C; IR (KBr): 3450, 3073, 2974, 1698, 1654, 1535, 1241, 1158, 847, 600 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 12.58 (br, 1H, NH), 7.40–7.38 (m, 2H, PhH), 7.22–7.19 (m, 2H, PhH), 3.85–3.58 (m, 2H, NCH₂), 3.45–3.36 (m, 2H, NCH₂), 2.49–3.46 (m, H, CH), 2.42–2.27 (m, 2H, CH₂), 1.96–1.89


(m, 2H, CH₂), 1.04 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 185.9, 173.2, 162.4 (d, *J* = 244.5 Hz), 156.7, 139.2, 129.5, 115.2 (d, *J* = 21.0 Hz), 86.6, 39.6, 38.4, 36.3, 29.9, 20.6, 15.6; HRMS (ESI) *m/z* calcd for C₁₆H₁₈FN₂O₂ [M+H]⁺, 289.1347; found, 289.1349.

7-Methyl-9-nitro-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (4e).




yellow solid: mp 228–232 °C; IR (KBr): 3395, 2976, 1705, 1623, 1500, 1394, 1243, 1140, 994, 811 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 11.75 (br, 1H, NH), 3.92–3.68 (m, 2H, NCH₂), 3.54–3.47 (m, 2H, NCH₂), 2.30–2.26 (m, H, CH), 2.64–2.47 (m, 2H, CH₂), 2.04–1.99 (m, 2H, CH₂), 1.24 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 172.3, 152.5, 106.3b 39.7, 39.1, 35.2b 27.9, 20.0, 15.5; HRMS (ESI) *m/z* calcd for C₉H₁₄N₃O₃ [M+H]⁺, 212.1030; found, 212.1030.

10-(4-Methoxybenzoyl)-8-methyl-2,3,4,5,8,9-hexahdropyrido[1,2-*a*][1,3]diazepin-7(1*H*)-one (4f).




White solid: mp 126–127.5 °C; IR (KBr): 3416, 2937, 1694, 1601, 1434, 1258, 1149, 999, 900, 642 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 11.63 (br, 1H, NH), 7.41 (d, *J* = 8.6 Hz, 2H, PhH), 6.92 (d, *J* = 8.3 Hz, 2H, PhH), 4.44–3.51 (m, 2H, NCH₂), 3.85 (s, 3H, OCH₃), 3.47–3.31 (m, 2H, NCH₂), 2.63–2.31 (m, 2H, CH₂), 2.50–2.42 (m, H, CH), 2.03–1.79 (m, 4H, CH₂CH₂), 1.18–1.16 (m, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 190.6, 174.5, 161.9, 160.3, 134.4, 128.7, 113.2, 92.5, 55.2, 45.1, 44.9, 37.8, 30.6, 26.5, 26.2, 14.6; HRMS (ESI) *m/z* calcd for C₁₈H₂₃N₂O₃ [M+H]⁺, 315.1703; found, 315.1707.

10-Benzoyl-8-methyl-2,3,4,5,8,9-hexahdropyrido[1,2-*a*][1,3]diazepin-7(1*H*)-one (4g).




White solid: mp 131–132 °C; IR (KBr): 3438, 2937, 1697, 1602, 1473, 1432, 1242, 1150, 997, 708 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 11.66 (br, 1H, NH), 7.31 (m, 5H, PhH), 4.33–3.45 (m, 2H, NCH₂), 3.41–3.25 (m, 2H, NCH₂), 2.47–2.35 (m, 2H, CH₂), 2.23–2.18 (m, H, CH), 1.81–1.71 (m, 4H, CH₂CH₂), 1.08–1.06 (d, J = 6.7 Hz, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 191.0, 174.6, 162.1, 142.1, 129.1, 128.1, 126.8, 92.4, 45.2, 44.9, 37.8, 30.3, 26.5, 26.1, 14.7; HRMS (ESI) *m/z* calcd for C₁₇H₂₁N₂O₂ [M+H]⁺, 285.1598; found, 285.1598.

6-Methyl-8-(4-methylbenzoyl)-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4h).




White solid: mp 162.5–164 °C; IR (KBr): 3291, 2962, 2817, 1686, 1634, 1525, 1439, 1286, 1033, 750 cm⁻¹; ¹H NMR (600 MHz, DMSO-d₆): δ = 9.34 (br, 1H, NH), 7.30 (d, J = 8.0 Hz, 2H, PhH), 7.20 (d, J = 7.9 Hz, 2H, PhH), 3.88–3.67 (m, 4H, NCH₂CH₂), 3.34 (s, 3H, CH₃), 2.59–2.56 (m, H, CH), 2.51–2.40 (m, 2H, CH₂), 1.07–1.06 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-d₆): δ = 189.1, 172.0, 156.5, 139.5, 139.0, 128.9, 127.4, 84.4, 43.3, 42.2, 36.8, 30.9, 21.4, 15.6; HRMS (ESI) *m/z* calcd for C₁₆H₁₉N₂O₂ [M+H]⁺, 271.1441; found, 271.1444.

8-Benzoyl-6-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4i).




White solid: mp 144.5–145.5 °C; IR (KBr): 3320, 2970, 1689, 1632, 1526, 1382, 1285, 1211, 1035, 736 cm⁻¹; ¹H NMR (600 MHz, DMSO-d₆): δ = 9.38 (br, 1H, NH), 7.42–7.38 (m, 5H, PhH), 3.89–3.68 (m, 4H, NCH₂CH₂), 2.58–2.55 (m, H, CH), 2.54–2.40 (m, 2H, CH₂), 1.08–1.07 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-d₆): δ = 189.1, 172.0, 156.6, 142.3, 129.4, 128.4, 127.2, 84.3, 43.3, 42.2, 36.8, 30.8, 15.6; HRMS (ESI) *m/z* calcd for C₁₅H₁₇N₂O₂ [M+H]⁺, 257.1285; found, 257.1284.

8-(4-Methoxybenzoyl)-6-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4j).




White solid: mp 164–165 °C; IR (KBr): 3416, 3285, 2971, 1683, 1633, 1577, 1496, 1289, 1167, 1022, 841 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 9.33 (br, 1H, NH), 7.40 (d, *J* = 8.7 Hz, 2H, PhH), 6.95 (d, *J* = 8.7 Hz, 2H, PhH), 3.89–3.67 (m, 4H, NCH₂CH₂), 3.79 (s, 3H, OCH₃), 2.64–2.62 (m, H, CH), 2.52–2.45 (m, 2H, CH₂), 1.09–1.08 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 188.5, 172.0, 160.4, 156.4, 134.6, 129.2, 113.6, 84.4, 55.6, 43.3, 42.2, 36.8, 31.1, 15.6; HRMS (ESI) *m/z* calcd for C₁₆H₁₉N₂O₃ [M+H]⁺, 287.1390; found, 287.1392.

8-(4-Chlorobenzoyl)-6-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4k).



White solid: mp 191.5–192.5 °C; IR (KBr): 3424, 2975, 1683, 1635, 1504, 1439, 1292, 1024, 758 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 9.44 (br, 1H, NH), 7.42–7.37 (m, 4H, PhH), 4.07–3.83 (m, 4H, NCH₂CH₂), 2.73–2.69 (m, H, CH), 2.57–2.45 (m, 2H, CH₂), 1.24–1.22 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 189.9, 172.6, 157.6, 140.0, 135.7, 128.8, 128.6, 85.4, 43.3, 42.5, 37.5, 31.1, 15.7; HRMS (ESI) *m/z* calcd for C₁₅H₁₆ClN₂O₂ [M+H]⁺, 291.0895; found, 291.0894.


8-(2-Chlorobenzoyl)-6-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4l).



White solid: mp 171–173°C; IR (KBr): 3415, 3306, 2966, 1691, 1634, 1513, 1283, 1036, 752 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 9.23 (br, 1H, NH), 7.32–7.31 (m, H, PhH), 7.23–7.20 (m, 2H, PhH), 7.16–7.14 (m, H, PhH), 3.98–3.77 (m, 4H, NCH₂CH₂), 2.51–2.48 (m, H, CH), 2.32–2.16 (m, 2H, CH₂), 1.13–1.12 (s, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 189.9, 172.3, 156.7, 140.7, 130.1, 129.6, 129.5, 127.7, 126.9,


85.5, 42.9, 42.1, 37.0, 29.1, 15.4; HRMS (ESI) m/z calcd for $C_{15}H_{16}ClN_2O_2 [M+H]^+$, 291.0895; found, 291.0897.

8-(4-Fluorobenzoyl)-6-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4m).




yellow solid: mp 154–155 °C; IR (KBr): 3415, 3311, 2979, 1683, 1637, 1600, 1441, 1286, 1155, 1034, 840 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 9.41 (br, 1H, NH), 7.49–7.46 (m, 2H, PhH), 7.11–7.08 (m, 2H, PhH), 4.08–3.84 (m, 4H, NCH₂CH₂), 2.75–2.72 (m, H, CH), 2.58–2.48 (m, 2H, CH₂), 1.25–1.24 (s, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 190.1, 172.6, 163.7 (d, J = 248.0 Hz), 157.6, 137.7, 129.6, 115.4 (d, J = 21.0 Hz), 85.4, 43.3, 42.5, 37.6, 31.1, 15.7; HRMS (ESI) m/z calcd for $C_{15}H_{16}FN_2O_2 [M+H]^+$, 275.1190; found, 275.1191.

6-Methyl-8-nitro-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (4n).



yellow solid: mp 240–250 °C; IR (KBr): 3415, 3238, 2989, 1700, 1625, 1491, 1376, 1289, 1184, 685 cm⁻¹; ¹H NMR (600 MHz, DMSO-*d*₆): δ = 9.53 (br, 1H, NH), 3.92–3.70 (m, 4H, NCH₂CH₂), 3.11–3.07 (m, H, CH), 2.74–2.43 (m, 2H, CH₂), 1.17–1.16 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 171.4, 153.0, 103.3, 43.8, 43.2, 35.6, 28.9, 15.8; HRMS (ESI) m/z calcd for $C_8H_{12}N_3O_3 [M+H]^+$, 198.0873; found, 198.0875.


9-(4-Methoxybenzoyl)-8-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (5a).



White solid: mp 154–156.5°C; IR (KBr): 3415, 2967, 1693, 1654, 1446, 1316, 1169, 1032, 837 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆): δ = 12.69 (br, 1H, NH), 7.25 (d, J =


8.5 Hz, 2H, PhH), 6.93 (d, J = 8.5 Hz, 2H, PhH), 3.93–3.52 (m, 2H, NCH₂), 3.78 (s, 3H, OCH₃), 3.57–3.34 (m, 2H, NCH₂), 2.81–2.77 (m, 2H, CH₂), 2.32–2.28 (m, H, CH), 1.94–1.93 (m, 2H, CH₂), 0.82–0.81 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 187.7, 169.6, 159.4, 155.7, 135.5, 128.1, 113.6, 92.4, 55.5, 39.9, 38.8, 38.4, 26.2, 21.3, 20.5; HRMS (ESI) *m/z* calcd for C₁₇H₂₁N₂O₃ [M+H]⁺, 301.1547; found, 301.1549.

9-Benzoyl-8-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (5b).




White solid: mp 125–127.5°C; IR (KBr): 3416, 2957, 1698, 1611, 1536, 1449, 1277, 1159, 713, 696 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆): δ = 12.58 (br, 1H, NH), 7.41–7.34 (m, 3H, PhH), 7.29–7.27 (m, 2H, PhH), 3.93–3.53 (m, 2H, NCH₂), 3.47–3.35 (m, 2H, NCH₂), 2.80–2.67 (m, 2H, CH₂), 2.31–2.27 (m, H, CH), 1.94–1.93 (m, 2H, CH₂), 0.81–0.80 (m, 3H, CH₃); ¹³C NMR (150 MHz, DMSO-*d*₆): δ = 188.0, 169.6, 155.8, 143.0, 128.3, 126.3, 92.3, 39.4, 38.8, 38.4, 26.1, 21.3, 20.4; HRMS (ESI) *m/z* calcd for C₁₆H₁₉N₂O₂ [M+H]⁺, 271.1441; found, 271.1442.

9-(4-Chlorobenzoyl)-8-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (5c).




White solid: mp 135.5–136.5 °C; IR (KBr): 3438, 2959, 1696, 1618, 1541, 1384, 1275, 1155, 837, 674 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 12.66 (br, 1H, NH), 7.28 (d, J = 8.0 Hz, 2H, PhH), 7.21 (d, J = 7.9 Hz, 2H, PhH), 4.03–3.55 (m, 2H, NCH₂), 3.45–3.35 (m, 2H, NCH₂), 2.73–2.61 (m, 2H, CH₂), 2.36–2.35 (m, H, CH), 1.99–1.95 (m, 2H, CH₂), 0.85 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 188.0, 169.8, 156.0, 140.7, 134.1, 128.4, 127.7, 93.0, 39.6, 38.8, 38.6, 26.2, 21.1, 20.6; HRMS (ESI) *m/z* calcd for C₁₆H₁₈ClN₂O₂ [M+H]⁺, 305.1051; found, 305.1049.

9-(4-Fluorobenzoyl)-8-methyl-1,2,3,4,7,8-hexahydro-6*H*-pyrido[1,2-*a*]pyrimidin-6-one (5d).




yellow solid: mp 130–132 °C; IR (KBr): 3437, 2958, 1697, 1599, 1529, 1383, 1153, 836 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 12.68 (br, 1H, NH), 7.26–7.24 (m, 2H, PhH), 7.00–6.97 (m, 2H, PhH), 4.03–3.54 (m, 2H, NCH₂), 3.45–3.35 (m, 2H, NCH₂), 2.75–2.72 (m, H, CH), 2.66–2.38 (m, 2H, CH₂), 1.99–1.95 (m, 2H, CH₂), 0.85–0.84 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 188.3, 169.8, 162.6 (d, *J* = 246.0 Hz), 156.0, 138.5, 128.1, 115.1 (d, *J* = 21.0 Hz), 93.0, 39.6, 38.8, 38.6, 26.2, 21.0, 20.7; HRMS (ESI) *m/z* calcd for C₁₆H₁₈FN₂O₂ [M+H]⁺, 289.1347; found, 289.1346.

8-Methyl-9-nitro-1,2,3,4,7,8-hexahydro-6H-pyrido[1,2-a]pyrimidin-6-one (5e).



yellow solid: mp 212–214.5 °C; IR (KBr): 3408, 3073, 2960, 1713, 1617, 1511, 1391, 1161, 1051, 955, 784 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 4.03–3.63 (m, 2H, NCH₂), 3.62–3.53 (m, 2H, NCH₂), 3.52–2.46 (m, H, CH), 2.74–2.51 (m, 2H, CH₂), 2.04–1.99 (m, 2H, CH₂), 1.73 (br, 1H, NH), 1.06 (d, *J* = 6.9 Hz, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 168.9, 151.8, 111.4, 39.3, 39.1, 38.0, 26.3, 19.9, 17.4; HRMS (ESI) *m/z* calcd for C₉H₁₄N₃O₃ [M+H]⁺, 212.1030; found, 212.1030.


10-(4-Methoxybenzoyl)-9-methyl-2,3,4,5,8,9-hexahdropyrido[1,2-a][1,3]diazepin-7(1*H*)-one (5f).



Light yellow solid: mp 162.5–163.5 °C; IR (KBr): 3449, 2953, 1695, 1697, 1474, 1432, 1266, 1149, 1000, 849 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 11.40 (br, 1H, NH), 7.27 (d, *J* = 8.6 Hz, 2H, PhH), 6.83 (d, *J* = 8.6 Hz, 2H, PhH), 4.61–3.46 (m, 2H, NCH₂), 3.76 (s, 3H, OCH₃), 3.12–3.08 (m, 2H, NCH₂), 2.86–2.62 (m, 2H, CH₂), 2.35–2.32 (m, H, CH), 1.85–1.65 (m, 4H, CH₂CH₂), 0.85 (d, *J* = 7.0 Hz, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 191.6, 171.3, 161.4, 160.2, 134.9, 128.1, 113.4,


98.8, 55.3, 45.4, 44.8, 40.8, 26.9, 26.8, 26.6, 19.5; HRMS (ESI) m/z calcd for $C_{18}H_{23}N_2O_3 [M+H]^+$, 315.1703; found, 315.1705.

10-Benzoyl-9-methyl-2,3,4,5,8,9-hexahydropyrido[1,2-*a*][1,3] diazepin-7(1*H*)-one (5g).




White solid: mp 157–159.5 °C; IR (KBr): 3290, 3066, 2951, 1696, 1596, 1471, 1310, 1147, 1004, 799, 710 cm^{-1} ; ^1H NMR (600 MHz, $\text{CDCl}_3 + \text{DMSO}-d_6$): $\delta = 7.05\text{--}6.97$ (m, 5H, PhH), 4.32–3.24 (m, 2H, NCH_2), 2.94–2.69 (m, 2H, NCH_2), 2.46–2.42 (m, H, CH), 2.38–2.00 (m, 2H, CH_2), 1.59–1.39 (m, 4H, CH_2CH_2), 1.44 (br, 1H, NH), 0.56 (d, $J = 6.9$ Hz, 3H, CH_3); ^{13}C NMR (150 MHz, $\text{CDCl}_3 + \text{DMSO}-d_6$): $\delta = 190.6, 170.1, 160.7, 141.5, 127.7, 127.3, 125.1, 97.3, 44.4, 43.8, 39.8, 38.0, 25.7, 25.6, 18.7$; HRMS (ESI) m/z calcd for $C_{17}H_{21}N_2O_2 [M+H]^+$, 285.1598; found, 285.1596.

7-Methyl-8-(4-methylbenzoyl)-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (5h).




White solid: mp 173–176 °C; IR (KBr): 3449, 3299, 2957, 1694, 1625, 1528, 1371, 1320, 1201, 1025, 769 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): $\delta = 9.50$ (br, 1H, NH), 7.32 (d, $J = 7.8$ Hz, 2H, PhH), 7.21 (d, $J = 7.7$ Hz, 2H, PhH), 4.12–3.77 (m, 4H, NCH_2CH_2), 3.09–3.07 (m, H, CH), 2.76–2.43 (m, 2H, CH_2), 2.39 (s, 3H, CH_3), 0.97–0.96 (m, 3H, CH_3); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 191.9, 168.8, 156.0, 138.9, 128.9, 126.4, 91.5, 42.5, 41.7, 39.7, 27.4, 22.0, 21.3$; HRMS (ESI) m/z calcd for $C_{16}H_{19}N_2O_2 [M+H]^+$, 271.1441; found, 271.1440.

8-Benzoyl-7-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (5i).




White solid: mp 138–139 °C; IR (KBr): 3289, 2958, 1695, 1625, 1524, 1439, 1328, 1207, 1027, 700 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 9.43 (br, 1H, NH), 7.31 (m, 5H, PhH), 4.04–3.71 (m, 4H, NCH₂CH₂), 2.96–2.93 (m, H, CH), 2.67–2.33 (m, 2H, CH₂), 0.88–0.87 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 192.0, 168.9, 156.2, 141.7, 129.0, 128.2, 126.4, 91.5, 42.6, 41.8, 39.8, 27.5, 19.6; HRMS (ESI) *m/z* calcd for C₁₅H₁₇N₂O₂ [M+H]⁺, 257.1285; found, 257.1286.

8-(4-Chlorobenzoyl)-7-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (5j).




White solid: mp 144–145.5 °C; IR (KBr): 3415, 3316, 2945, 1691, 1625, 1520, 1445, 1329, 1025, 671 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 9.53 (br, 1H, NH), 7.39–7.35 (m, 4H, PhH), 4.13–3.80 (m, 4H, NCH₂CH₂), 3.01–2.99 (m, H, CH), 2.76–2.43 (m, 2H, CH₂), 0.97–0.96 (m, 3H, CH₃); ¹³C NMR (125 MHz, CDCl₃): δ = 190.8, 169.1, 156.9, 140.4, 135.3, 128.8, 128.3, 91.8, 43.0, 42.3, 40.1, 27.9, 22.5; HRMS (ESI) *m/z* calcd for C₁₅H₁₆ClN₂O₂ [M+H]⁺, 291.0895; found, 291.0898.

8-(2-Chlorobenzoyl)-7-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (5k).




White solid: mp 228–229 °C; IR (KBr): 3415, 3319, 2959, 1697, 1630, 1529, 1375, 1208, 1027, 755 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 9.30 (br, 1H, NH), 7.31–7.18 (m, 4H, PhH), 4.05–3.75 (m, 4H, NCH₂CH₂), 2.68–2.58 (m, 2H, CH₂), 2.35–2.32 (m, H, CH), 0.84–0.83 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 189.0, 168.9, 156.1, 140.5, 130.2, 129.5, 127.8, 126.8, 91.8, 42.7, 41.8, 39.8, 27.4, 21.8; HRMS (ESI) *m/z* calcd for C₁₅H₁₆ClN₂O₂ [M+H]⁺, 291.0895; found, 291.0896.

8-(4-Fluorobenzoyl)-7-methyl-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (5l).



yellow solid: mp 143–144.5 °C; IR (KBr): 3290, 2961, 1703, 1622, 1527, 1371, 1226, 1026, 851, 772 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.39 (br, 1H, NH), 7.44–7.41 (m, 2H, PhH), 7.24–7.21 (m, 2H, PhH), 3.93–3.63 (m, 4H, NCH₂CH₂), 2.88–2.75 (m, 2H, CH₂), 2.27–2.24 (m, H, CH), 0.95–0.83 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ = 188.6, 168.5, 162.4 (d, *J* = 243.0 Hz), 155.8, 139.1, 129.0, 115.2 (d, *J* = 21.0 Hz), 90.5, 42.9, 41.8, 39.4, 27.6, 22.2; HRMS (ESI) *m/z* calcd for C₁₅H₁₆FN₂O₂ [M+H]⁺, 275.1190; found, 275.1191.


General procedure for the synthesis of compounds 6



HKA derivatives **1** (1.0 mmol), methacrylic anhydride **2a** or crotonic anhydride **2b** (1.2 mmol) and dry dioxane (10.0 mL) were placed in a 25 mL round-bottom flask and the mixture was stirred at reflux for 3–8 h. Upon completion, as monitored by TLC. Then the reaction mixture was cooled to room temperature and filtered to give the pure crude product, which was further washed with petroleum ether-EtOAc(1:1) to give pure product **6** with a yield of 87–93%.


Spectroscopic data of bicyclic pyridones derivatives 6

1-(4-Fluorobenzyl)-6-methyl-8-nitro-2,3,6,7-tetrahydroimidazo[1,2-*a*]pyridin-5(1*H*)-one (6a).




yellow solid: mp 188–189 °C; IR (KBr): 3415, 3063, 2974, 1711, 1609, 1436, 1380, 1221, 1156, 832 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 7.23–7.21 (m, 2H, PhH), 7.00–6.97 (m, 2H, PhH), 4.79 (d, J = 15 Hz, H, NCH), 4.73 (d, J = 15 Hz, H, NCH), 3.92–3.57 (m, 4H, NCH₂CH₂), 3.33–2.28 (m, H, CH), 2.63–2.59 (m, 2H, CH₂), 1.22–1.21 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 171.7, 162.7 (d, J = 246.0 Hz), 151.8, 130.5, 130.1, 116.0 (d, J = 21.0 Hz), 105.2, 54.3, 49.3, 41.3, 36.4, 30.8, 15.2; HRMS (ESI) *m/z* calcd for C₁₅H₁₇FN₃O₃ [M+H]⁺, 306.1248; found, 306.1249.

4-((6-Methyl-8-nitro-5-oxo-2,3,6,7-tetrahydroimidazo[1,2-a]pyridin-1(5H)-yl)methyl)benzonitrile (6b)




yellow solid: mp 166.5–167.5 °C; IR (KBr): 3432, 2978, 2230, 1694, 1606, 1255, 1189, 927, 823, 550 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 7.60 (d, J = 8.2 Hz, 2H, PhH), 7.40 (d, J = 8.1 Hz, 2H, PhH), 4.90 (d, J = 15.8 Hz, H, NCH), 4.79 (d, J = 15.7 Hz, H, NCH), 3.99–3.58 (m, 4H, NCH₂CH₂), 3.30–2.28 (m, H, CH), 2.64–2.60 (m, 2H, CH₂), 1.23–1.19 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 171.6, 151.9, 140.4, 132.7, 128.5, 118.3, 112.2, 105.6, 55.0, 50.1, 41.4, 36.3, 30.7, 15.1; HRMS (ESI) *m/z* calcd for C₁₆H₁₇N₄O₃ [M+H]⁺, 313.1295; found, 313.1296.

1-(4-Fluorobenzyl)-7-methyl-8-nitro-2,3,6,7-tetrahydroimidazo[1,2-a]pyridin-5(1H)-one (6c)



yellow solid: mp 150–152 °C; IR (KBr): 3394, 2953, 1710, 1590, 1437, 1145, 758, 597 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.17–7.16 (m, 2H, PhH), 6.99–6.96 (m, 2H, PhH), 4.82–4.65 (m, 2H, NCH), 3.99–3.60 (m, 4H, NCH₂CH₂), 3.58–3.56 (m, H, CH), 2.74–2.41 (m, 2H, CH₂), 1.00–0.99 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃+DMSO-d₆): δ = 172.4, 167.1 (d, J = 244.5 Hz), 155.5, 135.8, 134.7, 120.4 (d, J = 21.0 Hz), 115.7, 58.6, 54.9, 45.9, 43.3, 34.1, 23.8; HRMS (ESI) *m/z* calcd for C₁₅H₁₇FN₃O₃ [M+H]⁺, 306.1248; found, 306.1244.

4-((7-Methyl-8-nitro-5-oxo-2,3,6,7-tetrahydroimidazo[1,2-a]pyridin-1(5H)-yl)methyl)benzonitrile (6d)



yellow solid: mp 163.5–164.5 °C; IR (KBr): 3438, 2966, 2230, 1705, 1598, 1309, 1138, 757, 564 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 7.59 (d, *J* = 8.0 Hz, 2H, PhH), 7.35 (d, *J* = 7.9 Hz, 2H, PhH), 4.85–4.79 (m, 2H, NCH₂), 4.04–3.60 (m, 4H, NCH₂CH₂), 3.58–3.53 (m, H, CH), 2.74–2.42 (m, 2H, CH₂), 1.01–1.00 (m, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃): δ = 167.8, 150.4, 140.5, 132.7, 128.4, 118.3, 112.2, 111.6, 54.8, 50.4, 41.1, 38.5, 29.3, 19.2; HRMS (ESI) *m/z* calcd for C₁₆H₁₇N₄O₃ [M+H]⁺, 313.1295; found, 313.1292.

X-ray Structure and Data³ of 4j




Figure 1 X-Ray crystal structure of 4j

Table 1. Crystal data and structure refinement for **4j**.

Empirical formula	C16 H18 N2 O3		
Formula weight	286.32		
Temperature	293(2) K		
Wavelength	0.71073 Å		
Crystal system, space group	Triclinic, P-1		
Unit cell dimensions	a = 7.3821(12) Å	alpha = 94.965(2) deg.	
	b = 9.8440(17) Å	beta = 103.154(2) deg.	
	c = 10.9083(18) Å	gamma = 109.687(2) deg.	
Volume	715.2(2) Å ³		
Z, Calculated density	2, 1.330 Mg/m ³		
Absorption coefficient	0.093 mm ⁻¹		
F(000)	304		
Crystal size	0.30 x 0.20 x 0.18 mm		
Theta range for data collection	1.95 to 25.15 deg.		
Limiting indices	-8<=h<=8, -11<=k<=11, -13<=l<=13		
Reflections collected / unique	5725 / 2541 [R(int) = 0.0249]		
Completeness to theta = 25.15	99.6 %		
Max. and min. transmission	0.9835 and 0.9727		
Refinement method	Full-matrix least-squares on F ²		
Data / restraints / parameters	2541 / 0 / 192		
Goodness-of-fit on F ²	1.071		
Final R indices [I>2sigma(I)]	R1 = 0.0633, wR2 = 0.1611		
R indices (all data)	R1 = 0.0978, wR2 = 0.1910		
Largest diff. peak and hole	0.384 and -0.213 e.Å ⁻³		

Table 2. Bond lengths [Å] and angles [deg] for **4j**

N(1)-C(3)	1.368(4)	N(1)-C(2)-H(2B)	111.2
N(1)-C(7)	1.399(4)	C(1)-C(2)-H(2B)	111.2
N(1)-C(2)	1.474(4)	H(2A)-C(2)-H(2B)	109.1
N(2)-C(7)	1.332(4)	O(1)-C(3)-N(1)	120.4(3)
N(2)-C(1)	1.447(5)	O(1)-C(3)-C(4)	124.5(4)
N(2)-H(2)	0.8600	N(1)-C(3)-C(4)	115.0(3)
O(1)-C(3)	1.226(4)	C(5)-C(4)-C(16)	115.1(3)
O(2)-C(8)	1.253(4)	C(5)-C(4)-C(3)	113.4(3)
O(3)-C(12)	1.366(4)	C(16)-C(4)-C(3)	113.5(3)
O(3)-C(15)	1.429(4)	C(5)-C(4)-H(4)	104.4
C(1)-C(2)	1.535(6)	C(16)-C(4)-H(4)	104.4
C(1)-H(1A)	0.9700	C(3)-C(4)-H(4)	104.4
C(1)-H(1B)	0.9700	C(4)-C(5)-C(6)	115.7(3)
C(2)-H(2A)	0.9700	C(4)-C(5)-H(5A)	108.4
C(2)-H(2B)	0.9700	C(6)-C(5)-H(5A)	108.4
C(3)-C(4)	1.509(5)	C(4)-C(5)-H(5B)	108.4
C(4)-C(5)	1.463(5)	C(6)-C(5)-H(5B)	108.4
C(4)-C(16)	1.501(5)	H(5A)-C(5)-H(5B)	107.4
C(4)-H(4)	0.9800	C(7)-C(6)-C(8)	119.8(3)

C(5)-C(6)	1.517(4)	C(7)-C(6)-C(5)	115.3(3)
C(5)-H(5A)	0.9700	C(8)-C(6)-C(5)	124.9(3)
C(5)-H(5B)	0.9700	N(2)-C(7)-C(6)	130.9(3)
C(6)-C(7)	1.374(4)	N(2)-C(7)-N(1)	107.9(3)
C(6)-C(8)	1.426(4)	C(6)-C(7)-N(1)	121.1(3)
C(8)-C(9)	1.506(4)	O(2)-C(8)-C(6)	123.1(3)
C(9)-C(14)	1.387(4)	O(2)-C(8)-C(9)	117.5(3)
C(9)-C(10)	1.393(4)	C(6)-C(8)-C(9)	119.4(3)
C(10)-C(11)	1.371(4)	C(14)-C(9)-C(10)	117.5(3)
C(10)-H(10)	0.9300	C(14)-C(9)-C(8)	119.6(3)
C(11)-C(12)	1.383(4)	C(10)-C(9)-C(8)	122.9(3)
C(11)-H(11)	0.9300	C(11)-C(10)-C(9)	121.3(3)
C(12)-C(13)	1.392(5)	C(11)-C(10)-H(10)	119.3
C(13)-C(14)	1.382(4)	C(9)-C(10)-H(10)	119.3
C(13)-H(13)	0.9300	C(10)-C(11)-C(12)	120.4(3)
C(14)-H(14)	0.9300	C(10)-C(11)-H(11)	119.8
C(15)-H(15A)	0.9600	C(12)-C(11)-H(11)	119.8
C(15)-H(15B)	0.9600	O(3)-C(12)-C(11)	116.1(3)
C(15)-H(15C)	0.9600	O(3)-C(12)-C(13)	124.2(3)
C(16)-H(16A)	0.9600	C(11)-C(12)-C(13)	119.6(3)
C(16)-H(16B)	0.9600	C(14)-C(13)-C(12)	119.0(3)
C(16)-H(16C)	0.9600	C(14)-C(13)-H(13)	120.5
C(3)-N(1)-C(7)	124.9(3)	C(12)-C(13)-H(13)	120.5
C(3)-N(1)-C(2)	123.2(3)	C(13)-C(14)-C(9)	122.0(3)
C(7)-N(1)-C(2)	111.1(3)	C(13)-C(14)-H(14)	119.0
C(7)-N(2)-C(1)	113.6(3)	C(9)-C(14)-H(14)	119.0
C(7)-N(2)-H(2)	123.2	O(3)-C(15)-H(15A)	109.5
C(1)-N(2)-H(2)	123.2	O(3)-C(15)-H(15B)	109.5
C(12)-O(3)-C(15)	117.7(3)	H(15A)-C(15)-H(15B)	109.5
N(2)-C(1)-C(2)	103.5(3)	O(3)-C(15)-H(15C)	109.5
N(2)-C(1)-H(1A)	111.1	H(15A)-C(15)-H(15C)	109.5
C(2)-C(1)-H(1A)	111.1	H(15B)-C(15)-H(15C)	109.5
N(2)-C(1)-H(1B)	111.1	C(4)-C(16)-H(16A)	109.5
C(2)-C(1)-H(1B)	111.1	C(4)-C(16)-H(16B)	109.5
H(1A)-C(1)-H(1B)	109.0	H(16A)-C(16)-H(16B)	109.5
N(1)-C(2)-C(1)	102.8(3)	C(4)-C(16)-H(16C)	109.5
N(1)-C(2)-H(2A)	111.2	H(16A)-C(16)-H(16C)	109.5
C(1)-C(2)-H(2A)	111.2	H(16B)-C(16)-H(16C)	109.5

Table 3. Torsion angles [deg] for **4j**.

C(7)-N(2)-C(1)-C(2)	10.7(5)
C(3)-N(1)-C(2)-C(1)	172.1(3)
C(7)-N(1)-C(2)-C(1)	1.7(4)
N(2)-C(1)-C(2)-N(1)	-6.9(4)
C(7)-N(1)-C(3)-O(1)	176.2(3)
C(2)-N(1)-C(3)-O(1)	7.1(5)
C(7)-N(1)-C(3)-C(4)	-0.5(5)
C(2)-N(1)-C(3)-C(4)	-169.6(3)

O(1)-C(3)-C(4)-C(5)	153.8(4)
N(1)-C(3)-C(4)-C(5)	-29.6(5)
O(1)-C(3)-C(4)-C(16)	20.0(5)
N(1)-C(3)-C(4)-C(16)	-163.4(3)
C(16)-C(4)-C(5)-C(6)	177.5(3)
C(3)-C(4)-C(5)-C(6)	44.4(5)
C(4)-C(5)-C(6)-C(7)	-29.4(5)
C(4)-C(5)-C(6)-C(8)	151.3(3)
C(1)-N(2)-C(7)-C(6)	167.3(4)
C(1)-N(2)-C(7)-N(1)	-10.0(4)
C(8)-C(6)-C(7)-N(2)	1.2(6)
C(5)-C(6)-C(7)-N(2)	-178.1(3)
C(8)-C(6)-C(7)-N(1)	178.2(3)
C(5)-C(6)-C(7)-N(1)	-1.1(5)
C(3)-N(1)-C(7)-N(2)	-165.5(3)
C(2)-N(1)-C(7)-N(2)	4.8(4)
C(3)-N(1)-C(7)-C(6)	16.9(5)
C(2)-N(1)-C(7)-C(6)	-172.8(3)
C(7)-C(6)-C(8)-O(2)	8.8(5)
C(5)-C(6)-C(8)-O(2)	-171.9(3)
C(7)-C(6)-C(8)-C(9)	-171.6(3)
C(5)-C(6)-C(8)-C(9)	7.7(5)
O(2)-C(8)-C(9)-C(14)	46.4(4)
C(6)-C(8)-C(9)-C(14)	-133.2(3)
O(2)-C(8)-C(9)-C(10)	-132.3(3)
C(6)-C(8)-C(9)-C(10)	48.1(4)
C(14)-C(9)-C(10)-C(11)	0.4(4)
C(8)-C(9)-C(10)-C(11)	179.1(3)
C(9)-C(10)-C(11)-C(12)	2.0(5)
C(15)-O(3)-C(12)-C(11)	-177.7(3)
C(15)-O(3)-C(12)-C(13)	0.6(5)
C(10)-C(11)-C(12)-O(3)	176.5(3)
C(10)-C(11)-C(12)-C(13)	-1.8(5)
O(3)-C(12)-C(13)-C(14)	-179.0(3)
C(11)-C(12)-C(13)-C(14)	-0.8(5)
C(12)-C(13)-C(14)-C(9)	3.3(5)
C(10)-C(9)-C(14)-C(13)	-3.1(5)
C(8)-C(9)-C(14)-C(13)	178.2(3)

¹H NMR and ¹³C NMR spectra for compound 3




Figure 2a. ¹H NMR (500 MHz, DMSO-*d*6) spectra of compound 3




Figure 2b. ¹³C NMR (125 MHz, DMSO-*d*6) spectra of compound 3

¹H NMR and ¹³C NMR spectra for bicyclic pyridones 4

YUNNAN UNIVERSITY ASCEND III 600
Jinkiu-04 in DMSO
2016051107




Figure 3a ¹H NMR (600 MHz, DMSO-*d*6) spectra of compound 4a




Figure 3b ¹³C NMR (150 MHz, DMSO-*d*6) spectra of compound 4a




Figure 4a ^1H NMR (600 MHz, DMSO-*d*6) spectra of compound **4b**




Figure 4b ^{13}C NMR (150 MHz, DMSO-*d*6) spectra of compound **4b**

YUNNAN UNIVERSITY ASCEND III 600
Jinliu¹H DMSO
May26-201610




Figure 5a ¹H NMR (600 MHz, DMSO-*d*6) spectra of compound 4c




Figure 5b ¹³C NMR (150 MHz, DMSO-*d*6) spectra of compound 4c




Figure 6a ^1H NMR (600 MHz, DMSO-*d*6) spectra of compound **4d**




Figure 6b ^{13}C NMR (150 MHz, DMSO- d_6) spectra of compound **4d**

YUNNAN UNIVERSITY ASCEND AVIII 600
Jinliu-16 in CDCl₃
Jun08-2016-liujin01




Figure 7a ¹H NMR (600 MHz, CDCl₃) spectra of compound 4e

DEPT135

YUNNAN UNIVERSITY ASCEND AVIII 600
Jinliu-16 in CDCl₃
Jun08-2016-liujin01




Figure 7b ¹³C NMR (150 MHz, CDCl₃) spectra of compound 4e




Figure 8a ^1H NMR (500 MHz, DMSO-*d*6) spectra of compound **4f**




Figure 8b ^{13}C NMR (125 MHz, DMSO- d_6) spectra of compound **4f**

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu31 in CDCl₃
Jun16-2016-LJ




Figure 9a ¹H NMR (600 MHz, CDCl₃) spectra of compound 4g




Figure 9b ¹³C NMR (150 MHz, CDCl₃) spectra of compound 4g




Figure 10a ^1H NMR (600 MHz, DMSO-*d*6) spectra of compound 4h




Figure 10b ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) spectra of compound **4h**

YUNNAN UNIVERSITY ASCEND III 600
JinliuShan DMSO
May26-201604




Figure 11a ¹H NMR (600 MHz, DMSO-*d*₆) spectra of compound 4i




Figure 11b ¹³C NMR (150 MHz, DMSO-*d*₆) spectra of compound 4i




Figure 12a ^1H NMR (600 MHz, DMSO-*d*6) spectra of compound 4j




Figure 12b ^{13}C NMR (150 MHz, DMSO- d_6) spectra of compound **4j**




Figure 13a ^1H NMR (500 MHz, CDCl_3) spectra of compound **4k**




Figure 13b ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4k**




Figure 14a ^1H NMR (600 MHz, CDCl_3) spectra of compound **4l**




Figure 14b ^{13}C NMR (150 MHz, CDCl_3) spectra of compound **4l**




Figure 15a ^1H NMR (500 MHz, CDCl_3) spectra of compound **4m**




Figure 15b ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **4m**

YUNNAN UNIVERSITY ASCEND AVIII 600
Jinliu-22 in DMSO
Jun08-2016-liujinl0




Figure 16a ¹H NMR (600 MHz, DMSO-*d*6) spectra of compound 4n




Figure 16b ¹³C NMR (150 MHz, DMSO-*d*6) spectra of compound 4n

¹H NMR and ¹³C NMR spectra for bicyclic pyridones 5




Figure 17a ^1H NMR (500 MHz, DMSO-*d*6) spectra of compound **5a**




Figure 17b ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) spectra of compound **5a**




Figure 18a ^1H NMR (500 MHz, DMSO-*d*6) spectra of compound **5b**




Figure 18b ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) spectra of compound **5b**




Figure 19a ^1H NMR (600 MHz, CDCl_3) spectra of compound **5c**




Figure 19b ^{13}C NMR (150 MHz, CDCl_3) spectra of compound **5c**

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu 30-2 IN CDC13
Oct11-2016-liujin




Figure 20a ^1H NMR (600 MHz, CDCl_3) spectra of compound **5d**





Figure 20b ^{13}C NMR (150 MHz, CDCl_3) spectra of compound **5d**

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu-33 in CDCl₃
Jun20-2016-LJ04






Figure 22a ^1H NMR (600 MHz, CDCl_3) spectra of compound **5f**




Figure 22b ^{13}C NMR (150 MHz, CDCl_3) spectra of compound **5f**




Figure 23a ^1H NMR (600 MHz, DMSO-*d*6 + CDCl₃) spectra of compound **5g**




Figure 23b ^{13}C NMR (150 MHz, $\text{DMSO-}d_6 + \text{CDCl}_3$) spectra of compound **5g**




Figure 24a ^1H NMR (500 MHz, CDCl_3) spectra of compound **5h**




Figure 24b ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5h**

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu27 INCDC13
Jun14-2016-LJ07




Figure 25a ¹H NMR (600 MHz, CDCl₃) spectra of compound **5i**




Figure 25b ¹³C NMR (150 MHz, CDCl₃) spectra of compound **5i**




Figure 26a ^1H NMR (500 MHz, CDCl_3) spectra of compound **5j**




Figure 26b ^{13}C NMR (125 MHz, CDCl_3) spectra of compound **5j**

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu26 INCDC13
Jun14-2016-LJ04




Figure 27a ¹H NMR (600 MHz, CDCl₃) spectra of compound **5k**




Figure 27b ¹³C NMR (150 MHz, CDCl₃) spectra of compound **5k**




Figure 28a ^1H NMR (500 MHz, DMSO-*d*6) spectra of compound 5l




Figure 28b ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) spectra of compound 5l

¹H NMR and ¹³C NMR spectra for bicyclic pyridones 6

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu25 IN CDCl₃
Jun14-2016-LJ01




Figure 29a ¹H NMR (600 MHz, CDCl₃) spectra of compound 6a




Figure 29b ¹³C NMR (150 MHz, CDCl₃) spectra of compound 6a

YUNNAN UNIVERSITY ASCEND AVIII 600
JinLiu-36 in CDCl₃
Jun20-2016-LJ07




Figure 30a ¹H NMR (600 MHz, CDCl₃) spectra of compound 6b




Figure 30b ¹³C NMR (150 MHz, CDCl₃) spectra of compound 6b

YUNNAN UNIVERSITY AVIII 500
JinLiu-35-5 in CDCl₃
Oct17-2016-liujin




Figure 31a ¹H NMR (500 MHz, CDCl₃) spectra of compound 6c




Figure 31b ¹³C NMR (150 MHz, DMSO-*d*6+CDCl₃) spectra of compound 6c




Figure 32a ^1H NMR (600 MHz, CDCl_3) spectra of compound **6d**




Figure 32b ^{13}C NMR (150 MHz, CDCl_3) spectra of compound **6d**

References

- 1 (a) Z.-T. Huang and M.-X. Wang, *Synthesis*, 1992, **12**, 1273; (b) Z.-J. Li, and D. Charles, *Synth. Commun.*, 2001, **31**, 527.
- 2 Y.-F. Fan, S. Liu, N.-Y. Chen, X.-S. Shao, X.-Y. Xu and Z. Li, *Synlett*, 2015, **26**, 393.